What the Company Actually Does

Naprogenix operates as a cutting-edge research and development firm that has reinvented conventional plant drug discovery through its proprietary technology. The central focus is the screening and identification of complex plant-derived compounds, or metabolites, that can serve as lead molecules for commercial products. Unlike traditional methods that rely on the chemical synthesis of compounds followed by screening, Naprogenix integrates genomics with high-throughput molecular pharmacological screens to achieve its discoveries. The company is the exclusive licensee of a "Natural Product Genomics" technology that originated at the Kentucky Tobacco Research and Development Center.

This proprietary platform is an application of target-directed evolution of plant biosynthesis. The process involves directing a plant cell's metabolism toward producing a desired medicinal or commercial activity.

The Key Technological Process:

1. Target Expression: A specific target protein, relevant to a disease or desired agrochemical function, is expressed within the plant cells.
2. Selection Procedure: The cells are subjected to a selection procedure where the production of metabolites that interact with the target protein confers a survival advantage to the plant cell.
3. Mutagenesis and Evolution: A large, randomly mutated population of these plant cells has its genes activated at random. This process effectively "evolves" the plant cell's genome to biosynthesize metabolites that specifically engage the target protein.
4. Identification and Isolation: The cells that survive the selection procedure are then isolated to identify and extract the active natural products, which are often either known compounds produced at a much higher concentration or novel compounds altogether.

This technology is credited with providing a significant advantage by substituting plant biosynthesis for chemical synthesis and using target-directed selection instead of broad screening, enabling a rapid and efficient means of accessing the plant's entire genomic capacity to synthesize active metabolites.

Products and Services

Naprogenix???s business model is built around the applications of its technology, yielding a pipeline of potential products and services that can be broadly categorized into pharmaceutical leads, agrochemicals, and improved commercial-grade natural product production systems.

1. Pharmaceutical and Health & Well-being Leads

The company's platform is utilized to discover and optimize lead compounds for the treatment of various diseases and to address general health concerns (referred to as "positive use" products).

• Therapeutic Targets: Research and development efforts have historically focused on identifying active structures for chronic and debilitating diseases, including neurodegenerative diseases, certain types of cancer, and age-related macular degeneration. The company has conducted research on topics such as novel estrogen receptor ligands.
• Optimized Natural Products: By expressing multiple target proteins in a single plant cell, the technology can simultaneously promote the biosynthesis of desirable compounds while suppressing those with undesirable activities. This results in the production of "optimized" plant extracts or novel active compounds that are more suitable for drug development or nutritional applications than the original plant extract.

2. Agrochemical and Protective Compounds

Naprogenix develops compounds intended for protective uses, specifically within the agricultural sector.

• All-Natural Pesticides and Herbicides: The technology enables the discovery and production of natural products that can function as all-natural pesticides and herbicides. These represent a non-synthetic alternative to traditional agrochemicals.
• Bio-Activity Optimization: The platform's ability to screen for and optimize bio-activity in a native plant allows it to generate compounds that are effective and environmentally friendly leads for the agrochemical industry.

3. Biosynthetic Production Systems

A core service offered by the technology is the creation of highly efficient and proprietary production systems for natural products.

• High-Yield Production: For natural products that are too complex for chemical synthesis or are present at very low, uneconomical concentrations in the native plant, Naprogenix can generate mutant plant cells that significantly overproduce the active natural compound.
• Novel Production Patents: These genetically modified plant cells become a novel and patentable production system, overcoming a major hurdle for developing many plant metabolites into commercial drugs by making their separation and purification economically viable.

4. Commercialization Efforts and Spin-offs

A notable commercialization effort by Naprogenix was the spin-off of a separate entity to bring a specific class of products to market.

• Solidagex Inc.: Naprogenix created Solidagex, a new company focused on commercializing plant-beneficial compounds identified from goldenrod-based products using its proprietary technology. Solidagex targets the nutrition, cosmetics, and Ag-bio industries by offering proprietary ingredients that can deliver multiple benefits from a single source. Naprogenix intends to replicate this commercialization model for other active compounds identified in its extensive library of wild-type plant extracts.